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in descending order of frequency: BSL valve (Odds 3.5 IC 95% [1.3 –
9.6], p¼0.02), presence of an artifact (Odds 2.5 IC 95% [1.2 – 5.4],
p¼0.02) and BMI (Odds 1.1 IC 95% [1.0 – 1.2], p¼0.04).
CONCLUSIONS R-angio with dedicated motion compensation soft-
ware offers good image quality for on-line frame analysis in 72% of the
patients. Image quality predominantly depends on valve type, pres-
ence of artefacts and patient-related variables such as BMI.
“Disclaimer: The concepts and information presented in this paper are
based on research and are not commercially available.”
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BACKGROUND Stroke is a feared complication of trans-catheter aortic
valve replacement (TAVR). Carotid and vertebral artery duplex ul-
trasonography is routinely obtained prior to TAVR, but the signiﬁ-
cance of extracranial carotid and vertebral artery disease (CVD) on the
risk of stroke following TAVR is unknown. The purpose of this study is
to assess the impact of CVD on the risk of stroke following TAVR.
METHODS We reviewed 294 consecutive cases of TAVR at a single
tertiary care academic medical center from June, 2008 to March, 2015.
We included 263 patients who underwent routine carotid and verte-
bral artery duplex ultrasonography prior to TAVR in a retrospective
cohort study. Patients with at least 50% stenosis of a carotid or
vertebral artery were identiﬁed as having CVD, and patients were
stratiﬁed into 2 groups by the presence or absence of CVD. The pri-
mary outcome was stroke within 30 days of TAVR. We adjudicated
stroke by the guideline recommendations of the Valve Academic
Research Consortium. Secondary outcomes included 30-day mortality
and overall survival following TAVR. We used chi2 and Fischer’s exact
tests to compare categorical variables and independent samples t tests
to compare continuous variables. We used Kaplan Meier life table
analysis to assess overall survival. We included univariate predictors
of stroke at P<0.10 in a multivariable logistic regression to identify
predictors of stroke after TAVR.
RESULTS CVD was present in 51 (19%) patients. The CVD group had
higher rates of coronary artery disease, prior coronary artery bypass
surgery, and peripheral artery disease compared to the non-CVD
group. There was no signiﬁcant difference in the rate of prior stroke or
the burden of aortic atheroma by intra-operative trans-esophageal
echocardiogram between CVD and non-CVD patients. Trans-femoral
access was less common in the CVD group (55% vs. 77%, p<0.01).
Stroke occurred in 18 (6.8%) patients within 30 days after TAVR. No
patients with CVD suffered a stroke. There was no difference in 30-
day mortality (10% vs 4%, p¼0.11) and overall survival (log-rank test,
p¼0.89) between the CVD and non-CVD groups. CVD was not a sig-
niﬁcant predictor of stroke following TAVR by logistic regression. In a
multivariable model, there were no signiﬁcant independent pre-
dictors of stroke after TAVR, but baseline antiplatelet therapy showed
a trend towards a protective effect, and higher pre-TAVR mean aortic
valve gradient showed a trend toward increased risk of stroke (table).Predictors of Stroke
Following TAVR Odds Ratio95% Conﬁdence
Interval PPrior coronary artery
bypass surgery0.33 0.04 to 1.89 0.32Prior dyslipidemia 0.40 0.11 to 1.38 0.15Baseline antiplatelet
therapy0.29 0.08 to 1.02 0.05Aortic atherosclerosis
> 2mm thickness3.71 0.68 to 20.12 0.13Trans-aortic access 3.41 0.56 to 20.97 0.19Pre-TAVR mean aortic
valve gradient
(increasing
continuous variable
by mm Hg)1.05 1.00 to 1.11 0.07CONCLUSIONS CVD is not associated with an increased risk of stroke
or death following TAVR. The routine screening of CVD prior to TAVR
does not appear justiﬁed.
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BACKGROUND Patients with severe aortic stenosis who are referred
for transcatheter aortic valve replacement (TAVR) need to meet aortic
root and aortic annular anatomical inclusion criteria. We sought to
characterize the number of patients that could not have the currently
available transcatheter valves (Sapien XT and CoreValve).
METHODS We screened 400 patients with severe aortic stenosis who
were referred for TAVR between 2010-2014 who had had multi-de-
tector computed tomographic (MDCT) imaging. Annulus measure-
ments of the basal ring (short- and long-axis, area-derived diameter),
coronary ostia height, sinus area (SA), sino-tubular junction area
(STJ), calciﬁcation and eccentricity index (EI, 1-short axis/long axis)
were made.
RESULTS The vast majority of patients were able to be offered a
currently available TAVR valve (88%). We identiﬁed 49 patients who
were excluded for anatomical annular characteristics alone. Large
aortic annuli were the most common reason for anatomical exclusion
[704  79 mm2; (n¼ 39, 80 %)]. In addition these large annuli were
more elliptical (EI, 1.39  0.1) with more eccentric calciﬁcation (68 %).
The presence of low coronary heights (n¼6 mm: n¼19, 18 %) from the
aortic annular plane was the next most common reason. The left main
coronary artery was more commonly lower than the right coronary
artery and low coronary heights with effaced coronary sinuses
appeared occur together (n¼11, 57 %). Small aortic annuli were the
least common [290  50 mm2; n¼1, 2 %) cause for exclusion from
TAVR therapy. None of the patients who were excluded form TAVR
therapy had more than one annular reason for TAVR exclusion.
CONCLUSIONS Most patients with severe aortic stenosis who are
referred for TAVR can be offered a transcatheter valve. However, 12 %
of patients cannot be offered a therapy due to annular anatomical
exclusion criteria. This was primarily due to the presence of large
aortic annuli and low coronary heights.
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BACKGROUND The repositionable, fully retrievable, CE-marked
Lotus Valve is designed to facilitate controlled, precise positioning
and minimize paravalvular aortic regurgitation. Results to 3 years
post-implantation with Lotus have not yet been reported.
METHODS REPRISE I is a prospective, single-arm, 3-center feasibility
study designed to assess acute safety and performance of the 23mm
Lotus Valve in symptomatic patients with calciﬁed aortic stenosis who
were considered high surgical risk by the Heart Team.
RESULTS The Lotus Valve was implanted in 11 female patients with a
mean age 83.03.6 years and a mean STS score 4.92.5%). Frailty
measures included gait speed 6s (9/11), grip strength 18kg
(7/11), and cognitive dysfunction (5/11; deﬁned as a score <4 on the
